The global gastric motility disorder drugs market is slated to grow on the basis of rise in geriatric population who is at a higher risk of contracting these ailments. Increase in overall percentage of patients suffering from gastric motility disorders is another factor accelerating the demand for gastrointestinal motility drugs.
The companies operating in gastric motility disorder drugs market are working toward creating awareness campaigns in the under-developed economies of Asia Pacific, Middle East & Africa, and Latin America to widen their consumer base as these economies have been casual regarding stomach disorders since the last many years.
Gastric motility disorder drug market revolves around pharmaceutical products treating several gastric motility disorders such as gastroparesis, uncoordinated contractions of stomach muscles, gastroesophageal reflux disease, and various other conditions where movements of the abdomen are disrupted.
The drugs aim toward improvement of the movements of the belly and also emptying it by regulation of gastrointestinal hormones, reduction of production of acid, stimulation of muscles of the stomach, and providing relief from the symptoms resulting out of inappropriate stomach functioning.
However, challenges associated with gastric motility disorder drugs market include probable side-effects due to long-term medication.
Besides, mechanisms that underlie gastric motility disorders are not understood in entirety as of now, which is making the entire process of drug development complex. These factors may restrain the gastric motility disorder drugs market during the forecast period.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the World Gastroenterology Organisation, 46% of men and 49% of females suffer from some form of gastric disorders such as functional dyspepsia, functional constipation, functional diarrhea, IBS, and proctalgia.
The causes of gastric disorders include intake of low-fiber diet, not exercising properly, frequent traveling or other alterations in routine, excessive consumption of dairy products, stress, resisting urge of having a bowel movement, probably due to hemorrhoids, overusage of anti-diarrheal medications that weaken bowel muscle movements, consuming antacid medicines that contain aluminum or calcium, and others.
Increase in the frequency of gastrointestinal disorders and the need to combat them is thus contributing toward gastric motility disorder drugs market growth.
As per the National Institutes of Health, aging causes reduction in gastric contractile force and post-prandial peristalsis, which, in turn, increases the frequency of gastric emptying by 6 minutes on an average.
Generally, gastrointestinal symptoms in aged people underlie the organic pathologies. They can also come up in an atypical and a nuanced manner.
Aging is likely to affect gastrointestinal tract as well as accessory glandular organs (such as pancreas, gall bladder, and liver) by deteriorating the absorption and digestion functions.
As per the United Nations World Social Report 2023, the number of people aged 65 and above are projected to increase from 761 million in 2021 to 1.6 billion in 2050. Need to cope up with this irreversible trend at the global level is thus expanding the gastric motility disorder drugs market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest gastric motility disorder drugs market analysis, North America dominated the gastric motility medications landscape in 2023 and the dominance is expected to continue during the forecast period. This is attributed to the U.S. witnessing a higher percentage of expenditure on healthcare coupled with rapid adoption of advanced drugs.
Asia Pacific’s significant gastric motility disorder drugs market share is ascribed to countries like India and China emphasizing enhancement of local manufacturing capacities through the reforms and incentives rendered by the pharmaceutical industry over here.
As an outcome, various Western companies are coming forward to collaborate with domestic players to improve distribution network.
The key players in gastric motility disorder drugs market are engaging in new product launch to strengthen their position in the market. For instance, in April 2022, Ardelyx, Inc. announced that it had launched IBSRELA, the first and only inhibitor meant to treat irritable bowel syndrome with constipation (UBS-C) in individuals aged 18 and above. The product has been approved by the U.S. FDA.
The key participants are also engaging in various inorganic modes of expansion to sustain themselves. For instance, in February 2022, Evoke Pharma, Inc. extended its agreement with EVERSANA Life Science Service LLC to commercialize and distribute Gimoti (metoclopramide) nasal spray in the U.S. by the end of 2026.
Pfizer Inc., The Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, The Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Endo International plc, Eisai Co. Ltd., Ferring Pharmaceuticals, and UCB are some of the key players covered in the gastric motility disorder drugs market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 57.6 Bn |
| Market Forecast (Value) in 2034 | US$ 102.7 Bn |
| Growth Rate (CAGR) | 5.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 57.6 Bn in 2023
It is projected to grow at a CAGR of 5.4% from 2024 to 2034
Growing prevalence of gastric disorders and increase in geriatric population
Retail pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Pfizer Inc., The Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, The Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Endo International plc, Eisai Co. Ltd., Ferring Pharmaceuticals, and UCB
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Gastric Motility Disorder Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Gastric Motility Disorder Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Antacids
6.3.2. Antidiarrheals
6.3.3. Calcium-channel Blockers
6.3.4. H2 Blockers
6.3.5. Others (Proton Pump Inhibitors, etc.)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Disorder Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disorder Type, 2020-2034
7.3.1. Upper Digestive Tract
7.3.1.1. Achalasia
7.3.1.2. Gastroesophageal Reflux Disease (GERD)
7.3.1.3. Gastroparesis
7.3.1.4. Dumping Syndrome
7.3.2. Lower Digestive Tract
7.3.2.1. Intestinal Pseudo-obstruction
7.3.2.2. Small Intestinal bacterial Overgrowth (SIBO)
7.3.2.3. Pelvic Dyssynergia
7.3.2.4. Hirschsprung’s Disease
7.4. Market Attractiveness Analysis, by Disorder Type
8. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gastric Motility Disorder Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. Antacids
10.3.2. Antidiarrheals
10.3.3. Calcium-channel Blockers
10.3.4. H2 Blockers
10.3.5. Others (Proton Pump Inhibitors, etc.)
10.4. Market Value Forecast, by Disorder Type, 2020-2034
10.4.1. Upper Digestive Tract
10.4.1.1. Achalasia
10.4.1.2. Gastroesophageal Reflux Disease (GERD)
10.4.1.3. Gastroparesis
10.4.1.4. Dumping Syndrome
10.4.2. Lower Digestive Tract
10.4.2.1. Intestinal Pseudo-obstruction
10.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
10.4.2.3. Pelvic Dyssynergia
10.4.2.4. Hirschsprung’s Disease
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Disorder Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Gastric Motility Disorder Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Antacids
11.3.2. Antidiarrheals
11.3.3. Calcium-channel Blockers
11.3.4. H2 Blockers
11.3.5. Others (Proton Pump Inhibitors, etc.)
11.4. Market Value Forecast, by Disorder Type, 2020-2034
11.4.1. Upper Digestive Tract
11.4.1.1. Achalasia
11.4.1.2. Gastroesophageal Reflux Disease (GERD)
11.4.1.3. Gastroparesis
11.4.1.4. Dumping Syndrome
11.4.2. Lower Digestive Tract
11.4.2.1. Intestinal Pseudo-obstruction
11.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
11.4.2.3. Pelvic Dyssynergia
11.4.2.4. Hirschsprung’s Disease
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Disorder Type
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Gastric Motility Disorder Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. Antacids
12.3.2. Antidiarrheals
12.3.3. Calcium-channel Blockers
12.3.4. H2 Blockers
12.3.5. Others (Proton Pump Inhibitors, etc.)
12.4. Market Value Forecast, by Disorder Type, 2020-2034
12.4.1. Upper Digestive Tract
12.4.1.1. Achalasia
12.4.1.2. Gastroesophageal Reflux Disease (GERD)
12.4.1.3. Gastroparesis
12.4.1.4. Dumping Syndrome
12.4.2. Lower Digestive Tract
12.4.2.1. Intestinal Pseudo-obstruction
12.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
12.4.2.3. Pelvic Dyssynergia
12.4.2.4. Hirschsprung’s Disease
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Disorder Type
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Gastric Motility Disorder Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Antacids
13.3.2. Antidiarrheals
13.3.3. Calcium-channel Blockers
13.3.4. H2 Blockers
13.3.5. Others (Proton Pump Inhibitors, etc.)
13.4. Market Value Forecast, by Disorder Type, 2020-2034
13.4.1. Upper Digestive Tract
13.4.1.1. Achalasia
13.4.1.2. Gastroesophageal Reflux Disease (GERD)
13.4.1.3. Gastroparesis
13.4.1.4. Dumping Syndrome
13.4.2. Lower Digestive Tract
13.4.2.1. Intestinal Pseudo-obstruction
13.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
13.4.2.3. Pelvic Dyssynergia
13.4.2.4. Hirschsprung’s Disease
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospitals
13.5.2. Biopharmaceutical Companies
13.5.3. Research Organizations and Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Disorder Type
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Gastric Motility Disorder Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Antacids
14.3.2. Antidiarrheals
14.3.3. Calcium-channel Blockers
14.3.4. H2 Blockers
14.3.5. Others (Proton Pump Inhibitors, etc.)
14.4. Market Value Forecast, by Disorder Type, 2020-2034
14.4.1. Upper Digestive Tract
14.4.1.1. Achalasia
14.4.1.2. Gastroesophageal Reflux Disease (GERD)
14.4.1.3. Gastroparesis
14.4.1.4. Dumping Syndrome
14.4.2. Lower Digestive Tract
14.4.2.1. Intestinal Pseudo-obstruction
14.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
14.4.2.3. Pelvic Dyssynergia
14.4.2.4. Hirschsprung’s Disease
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Disorder Type
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. The Takeda Pharmaceutical Company Limited
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Janssen Pharmaceuticals
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sun Pharmaceutical Industries Ltd.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AbbVie Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Eli Lilly and Company
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. The Bristol-Myers Squibb Company
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Daiichi Sankyo Company, Limited
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bausch Health Companies Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Mallinckrodt Pharmaceuticals
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Endo International plc
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Eisai Co. Ltd.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Ferring Pharmaceuticals
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. UCB
15.3.15.1. Company Overview
15.3.15.2. Product Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview
List of Tables
Table 01: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 02: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
Table 03: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 07: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
Table 08: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 11: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
Table 12: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 15: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
Table 16: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 19: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
Table 20: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 23: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
Table 24: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Drug Class, 2023
Figure 03: Global Gastric Motility Disorder Drugs Market Value Share, by Drug Class, 2023
Figure 04: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Disorder Type, 2023
Figure 05: Global Gastric Motility Disorder Drugs Market Value Share, by Disorder Type, 2023
Figure 06: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 07: Global Gastric Motility Disorder Drugs Market Value Share, by Distribution Channel, 2023
Figure 08: Global Gastric Motility Disorder Drugs Market Value Share, by Region, 2023
Figure 09: Global Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 11: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
Figure 13: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
Figure 14: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 22: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
Figure 23: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
Figure 26: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 31: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
Figure 32: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
Figure 35: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 40: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
Figure 41: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
Figure 44: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 49: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
Figure 50: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
Figure 53: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 58: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
Figure 59: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
Figure 62: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gastric Motility Disorder Drugs Market
